The expanded deal into multiple therapeutic areas has been expanded owing to Jubilant’s skill sets in several therapeutic areas.
The collaboration has been expanded to use Jubilant’s drug discovery capabilities on selected drug discovery targets to advance programs in multiple disease areas.
Under the deal, Jubilant will conduct research services as well as deliver preclinical candidates to Janssen for potential development and commercialization.
Apart from research funding, Jubilant will also receive milestones and royalties should Janssen successfully progress the assets into clinical development and commercialization.
Majority of the research will be undertaken at Jubilant Biosys, India and some parts at Jubilant Discovery Center, US.
Janssen Pharmaceutica is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Jubilant Biosys president Subir Basak said the company is happy to announce the expansion of the collaboration and look forward to discovering Novel Chemical Entities (NCEs) that address the unmet medical needs in these important disease areas.
"Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts. We look forward to a long, and mutually beneficial, partnership," Basak said.